Documented rates, risk factors, and response protocols for anaphylactic reactions.
Anaphylaxis is a severe, potentially life-threatening allergic reaction that can occur within minutes of exposure to an allergen. In the context of vaccination, anaphylaxis is a recognised adverse event that is monitored by all major vaccine safety systems worldwide.
Anaphylaxis following vaccination is rare. When it does occur, it is almost always within 15–30 minutes of administration — which is why all vaccination sites maintain a mandatory observation period and keep epinephrine (adrenaline) on hand.
Studies estimate anaphylaxis following vaccination occurs at approximately 1.31 cases per 1 million vaccine doses administered across all vaccines (CDC, 2016).
Following COVID-19 mRNA vaccine rollout, VAERS and VSD data indicated anaphylaxis rates of approximately 2–5 cases per million doses — higher than older vaccines but still rare.
Some vaccines carry slightly higher anaphylaxis rates, including certain influenza vaccines and the HPV vaccine, though all rates remain below 10 per million doses.
Known risk factors include prior allergic reactions to vaccines or vaccine components (e.g. PEG, polysorbate 80, gelatin, neomycin), and mast cell disorders. A prior anaphylactic episode to a vaccine is a contraindication to re-administration.
Anaphylaxis typically presents within 15 minutes of vaccination (though rarely up to 30 minutes). Key symptoms include:
Hives, flushing, swelling (angioedema)
Throat tightening, wheezing, shortness of breath
Rapid or weak pulse, drop in blood pressure
Nausea, vomiting, abdominal cramping
Dizziness, loss of consciousness
Clinical Note: Two or more organ systems involved simultaneously indicates anaphylaxis rather than a simple allergic reaction.
Standard post-vaccination anaphylaxis management:
Intramuscular epinephrine (0.3–0.5mg in adults, 0.01mg/kg in children) is the first-line treatment. It must be administered immediately — antihistamines are NOT a substitute for epinephrine in anaphylaxis.
All vaccination sites are required to observe patients for a minimum of 15–30 minutes post-vaccination. High-risk individuals (prior allergic reactions) should be observed for 30 minutes.
All vaccination sites must have a protocol for calling emergency services immediately if anaphylaxis is suspected. Patients must be transported to an emergency facility even after epinephrine administration due to risk of biphasic reaction.
All cases of post-vaccination anaphylaxis must be reported to VAERS by healthcare providers. This reporting is mandatory, not optional.
Common vaccine components associated with allergic reactions:
Present in mRNA COVID-19 vaccines (Pfizer-BioNTech, Moderna). Associated with rare anaphylaxis.
Present in many traditional vaccines. Cross-reactive with PEG in some individuals.
Present in MMR, varicella, and some influenza vaccines. A known allergen, particularly in individuals with gelatin food allergy.
An antibiotic present in some vaccines. Associated with contact dermatitis more than anaphylaxis.
Present in some influenza and yellow fever vaccines. Relevant for individuals with severe egg allergy.
Some vaccine packaging uses latex-containing stoppers. Relevant for individuals with latex allergy.